Elan Corporation Plc News

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

ELAN has ceased the two highest doses in clinical trials of one of its main Alzheimera TMs treatments following the deaths of nine people, even though those deaths have not been directly linked to the trial.

High doses of drugs, Alzheimer's, and Elan just don't go well together. Elan had to drop the highest dose of bapineuzumab earlier this year and now a second drug, ELND005, will need to do the same.

Elan Drug Technologies, a business unit of Elan Corporation, plc announces the approval by the Japanese Ministry of Health, Labour and Welfare of EMEND A for the treatment of cancer chemotherapy-induced nausea and vomiting.

Gilead Sciences couldn't convince the Food and Drug Administration last year to approve its inhaled antibiotic treatment for cystic fibrosis-related infections, but now it's got a panel of experts on its side.

Elan Corporation, plc today announced that it will present at the Deutsche Bank Securities Biotech Boston Confab Conference, on Tuesday, December 15, 2009, at 10:30 a.m. Eastern Time and 3:30 p.m. GMT.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

There are two rules in negotiations. Don't be the first to name a number and don't get in a bidding war with yourself.

Teva Pharmaceutical has decided it's not worth waiting for the U.S. government to establish a pathway for approval of generic versions of biologic drugs.

DUBLIN, Ireland-- --Elan Corporation, plc today announced that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference, on Tuesday, November 17, 2009 a... 11/11/2009 - 01:55 AM print24 lowers prices RADEBEUL, Germany-- --Klaus Sauer, Managing Director of print24, explained the company's strategy: "Our philosophy is to deliver ...

Here's what Jim Cramer had to say about some of the stocks that callers offered up during the "Mad Money Lightning Round" Tuesday evening.

Johnson & Johnson plans to cut up to 7 percent of its workforce in order to generate cost savings needed to finance increasingly costly drug research and to weather future challenges, the diversified healthcare company said on Tuesday.

Johnson & Johnson's CEO has given an interview to the Financial Times explaining his company's strategy with acquisitions.

Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, silicon-wafer maker MEMC Electronic Materials has earned a coveted five-star ranking .

InvestorSoup.com announces an investment report featuring Elan Corp. Plc. . The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, Irish biotech Elan has earned a respected four-star ranking .

Shares of Biogen Idec fell Friday as European regulators investigate reports of 23 cases of Tysabri patients with a potentially fatal brain infection.

SHARES IN Elan slumped yesterday after the European Medicinces Agency announced a review of the risks and benefits of its key multiple sclerosis drug Tysabri in the wake of 23 cases of a rare and potentially fatal brain disease since it came to market.

Partners Biogen Idec and Elan Corp. led drug stocks lower early Friday as shares of the companies fell on news that European regulators were reviewing the safety of their multiple sclerosis drug Tysabri.

Earnings from continuing operations were 77 cents a share. Sales were $936 million compared to $1.12 billion a year ago.